SOCM
DSGN icon

SR One Capital Management’s Design Therapeutics DSGN Stock Holding History

SR One Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.4M Hold
6,526,476
– – 9.09% 5
2026
Q1 		$69.4M Hold
6,526,476
– – 7.59% 5
2025
Q4 		$61.2M Hold
6,526,476
– – 8.67% 4
2025
Q3 		$49.1M Hold
6,526,476
– – 7.11% 6
2025
Q2 		$22M Hold
6,526,476
– – 4.77% 7
2025
Q1 		$25.2M Hold
6,526,476
– – 6.47% 6
2024
Q4 		$40.3M Hold
6,526,476
– – 9.82% 4
2024
Q3 		$35.1M Hold
6,526,476
– – 7.04% 5
2024
Q2 		$21.9M Hold
6,526,476
– – 6.85% 6
2024
Q1 		$26.3M Hold
6,526,476
– – 7.22% 5
2023
Q4 		$17.3M Hold
6,526,476
– – 7.26% 3
2023
Q3 		$15.4M Hold
6,526,476
– – 7.89% 3
2023
Q2 		$41.1M Hold
6,526,476
– – 17.73% 2
2023
Q1 		$37.7M Hold
6,526,476
– – 14.03% 2
2022
Q4 		$67M Buy
6,526,476
+900,000
+16% +$12.2M 24.44% 2
2022
Q3 		$94.1M Hold
5,626,476
– – 43.01% 2
2022
Q2 		$78.8M Hold
5,626,476
– – 38.55% 2
2022
Q1 		$90.9M Hold
5,626,476
– – 46.52% 1
2021
Q4 		$120M Buy
+5,626,476
New +$96.6M 68.08% 1

Other funds holding DSGN

LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

SR One Capital Management's DSGN Position: Q2 2026 in Review

SR One Capital Management held its Design Therapeutics (DSGN) position steady in Q2 2026 at 6,526,476 shares worth $94.4M. The position accounts for 9.09% of the portfolio, ranked #5.

SR One Capital Management first reported a position in DSGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $120M in Q4 2021. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • SR One Capital Management held 6,526,476 shares of Design Therapeutics worth $94.4M as of Q2 2026.
  • SR One Capital Management left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up 9.09% of SR One Capital Management's portfolio in Q2 2026, its #5 holding.
  • SR One Capital Management first reported a position in Design Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • SR One Capital Management's Design Therapeutics position peaked at $120M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.